Freenome (NASDAQ:FRNM) Upgraded at Jefferies Financial Group

Freenome (NASDAQ:FRNM) was upgraded by equities research analysts at Jefferies Financial Group to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

FRNM has been the topic of a number of other reports. Leerink Partners assumed coverage on Freenome in a research note on Friday. They set an “outperform” rating and a $18.00 price target on the stock. TD Cowen assumed coverage on Freenome in a research note on Tuesday. They issued a “buy” rating for the company. Finally, BTIG Research assumed coverage on Freenome in a report on Monday. They issued a “buy” rating and a $17.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, Freenome presently has an average rating of “Strong Buy” and a consensus target price of $17.33.

Freenome Price Performance

NASDAQ:FRNM opened at $13.00 on Monday. Freenome has a fifty-two week low of $9.97 and a fifty-two week high of $14.26. The company has a market cap of $106.08 million, a P/E ratio of -216.63 and a beta of 0.35.

About Freenome

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.